Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS9 | O00182 | 3/20 | 0.55 |
| ▸ | LGALS1 | P09382 | 3/20 | 0.55 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.55 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GAPDH | P04406 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20149722 | 0.93 | LGALS3 (0.65) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPOLB | |
| SCHEMBL14356282 | 0.90 | LGALS9 (0.54) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPOLB | |
| SCHEMBL14602169 | 0.89 | PTPN1 (0.55) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPOLB | |
| SCHEMBL5379160 | 0.89 | PTPN1 (0.55) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPOLB | |
| SCHEMBL10062436 | 0.89 | PTPN1 (0.55) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPOLB | |
| SCHEMBL23269817 | 0.89 | LGALS9 (0.53) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPOLB | |
| SCHEMBL20693186 | 0.89 | PTPN1 (0.55) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPOLB | |
| SCHEMBL21007943 | 0.89 | PTPN1 (0.55) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPOLB | |
| SCHEMBL18574064 | 0.89 | PTPN1 (0.55) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPOLB | |
| SCHEMBL14571284 | 0.89 | PTPN1 (0.55) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009620-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | OPKO PHARMACEUTICALS, LLC. | 2021-01-14 | — | — | US | disclosed |
| US-10829509-B2 | Pure heptasulfated disaccharides having improved oral bioavailability | OPKO PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190185503-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | OPKO PHARMACEUTICALS, LLC. | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009620-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | SI, GYS1, UGGT1 | LGALS9 441/4885LGALS1 375/4885LGALS3 593/4885 |
| US-10829509-B2 | Pure heptasulfated disaccharides having improved oral bioavailability | SI, GYS1, UGGT1 | LGALS9 441/4885LGALS1 375/4885LGALS3 593/4885 |
| US-20190185503-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | SI, GYS1, UGGT1 | LGALS9 441/4885LGALS1 375/4885LGALS3 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.